Q3 2026 results - Tuesday, October 27, 2026
Press release: English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB)
Interim financial report (PDF 0.4 MB)
Download the podcast (MP3 34 MB)
Download the interactive presentation (PDF 3.2 MB)
Novartis Q3 2026 impact and sustainability update (PDF 2.2 MB)
| Key figures1 | Q3 2026 (USD m) | Q3 2025 (USD m) | % change (USD/cc) |
|---|---|---|---|
| Net sales | 14,522 | 13,909 | 4 (cc: 4) |
| Operating income | 1,843 | 4,501 | -59 (cc: -61) |
| Net income | 1,196 | 3,930 | -70 (cc: -71) |
| EPS (USD) | 0.63 | 2.04 | -69 (cc: -70) |
| Free cash flow | 5,111 | 6,217 | -18 |
Core | |||
| Operating income | 6,036 | 5,460 | 11 (cc: 10) |
| Net income | 4,655 | 4,330 | 8 (cc: 6) |
| EPS (USD) | 2.46 | 2.25 | 9 (cc: 8) |
- Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 45 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.